Clinical Trials Can Improve Outcomes And Lower Costs.
Trial Library enables access to research as a care option by providing personalized research recommendations and patient navigation.
Cancer Claims Aren't Just Growing. They are Compounding.
Cancer care is inherently complex and multi-specialist - risking inadvertent out-of-network exposure for members. Trial Library’s specialized navigation enables expanded access to research as a care option through network-aware provider selection at diagnosis and keeping patients retained in a single system. Navigation can result in a 35% reduction in patients lost to other health systems suggest navigation is one of the highest-leverage investments a health plan or employer can make for oncology cost management (reference).
- A single member can breach a $150K stop-loss threshold.
- Standard interventions manage costs at the margins not structurally.
- Lasers, rate hikes, and exclusions follow threatening long-term sustainability.
When A Member Enrolls In A Manufacturer-Sponsored Trial, The Sponsor Pays For The Investigational Drug
In industry-sponsored trials, the investigational drug is covered by the sponsor. Federal law (ACA Section 2709) requires health plans to cover routine care costs — labs, imaging, and office visits.
The result is a structural shift in cost exposure:
End-to-end Enrollment Infrastructure Built For Health Plans & Employers
Trial Library's platform spans every stage of the research journey. Deploy the full platform or the capabilities that complement your existing infrastructure.
Our Intelligent Navigation OS supports patients from identification through completion surfacing barriers and providing comprehensive support.
3000+ providers, 840+ actively participating sites. Trial Library's robust platform deploys proven methods for supporting providers
See what trial access could mean for your highest-cost members.
Clinical trials are undergoing a paradigm shift, from “big-pharma-experiment” to life saving care option. Your plan has the opportunity to cleanly differentiate within cancer treatment and move with this shift, strengthening relationships across providers, research networks, and patients.
